Why is Suven Life Sciences Ltd falling/rising?

Recent Price Movement and Market Context

On 29 December, Suven Life Sciences witnessed a notable intraday low of ₹162.30, marking a 2.26% drop from previous levels. The weighted average price indicates that a larger volume of shares traded closer to this low, signalling selling pressure. The stock has underperformed its sector by 0.82% on the day and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a bearish sentiment among traders and investors in the short term.

Despite this recent decline, the stock has delivered robust returns over longer periods. It has outperformed the Sensex significantly, generating a 27.45% return over the past year compared to the Sensex’s 7.62%. Over three years, the stock’s gains have been even more pronounced at 134.98%, dwarfing the benchmark’s 38.54%. However, the past week and month have seen the stock fall by 4.71%, underperforming the Sensex’s modest declines of around 1% in the same periods.

Institutional Interest and Trading Activity

Institutional investors have increased their stake in Suven Life Sciences by 0.59% over the previous quarter, now collectively holding 4.56% of the company. This rise in institutional participation often reflects confidence in the company’s prospects or value at current prices, given their superior analytical capabilities compared to retail investors. Additionally, delivery volumes on 26 December rose by 4.7% against the five-day average, indicating heightened investor activity despite the price decline.

Fundamental Challenges Weighing on the Stock

Despite the strong market returns, Suven Life Sciences faces significant fundamental headwinds. Over the last five years, the company’s net sales have declined at an annualised rate of 23.11%, while operating profit has plummeted by 186.11%. This negative growth trajectory highlights persistent operational difficulties. The company’s ability to service debt is also weak, with an average EBIT to interest ratio of -149.78, indicating that earnings before interest and tax are insufficient to cover interest expenses.

Moreover, the company has reported negative results for five consecutive quarters. The profit before tax excluding other income for the latest quarter stood at a loss of ₹81.09 crores, a 69.2% decline compared to the average of the previous four quarters. Similarly, the net profit after tax for the quarter was a loss of ₹77.31 crores, down 67.9% from the prior quarterly average. Operating cash flow for the year is also at a low of ₹-47.39 crores, underscoring cash generation issues.

The stock’s risk profile is elevated due to its negative EBITDA and deteriorating profitability. While the stock price has risen by 27.45% over the past year, profits have fallen by 45.2%, suggesting that the market’s valuation may not fully reflect the company’s operational struggles.

Conclusion: Balancing Strong Returns Against Weak Fundamentals

Suven Life Sciences Ltd’s recent share price decline reflects a market response to its weak operational performance and deteriorating financial metrics, despite the company’s impressive long-term returns relative to the broader market. The stock’s underperformance over the past week and month, combined with its trading below key moving averages and negative quarterly results, signals caution for investors. While institutional interest remains steady and liquidity is adequate, the company’s ongoing losses and poor cash flow generation present significant risks.

Investors should weigh the stock’s attractive historical returns against its fundamental challenges and recent price weakness. The current environment suggests that the market is factoring in these risks, resulting in the recent downward pressure on the share price.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →